OSE Immunotherapeutics Expands Lusvertikimab into Chronic Pouchitis and Hidradenitis Suppurativa

Event summary

  • OSE Immunotherapeutics targets chronic pouchitis and hidradenitis suppurativa as new indications for lusvertikimab, leveraging IL-7R biology.
  • First Phase 2 trial expected to start in H2 2026, subject to financing.
  • Chronic pouchitis offers a rare-disease path with a well-defined patient population (~45,000 across EU, NA, Japan).
  • Hidradenitis suppurativa presents a large dermatology market opportunity (~9.5M patients across EU, NA, Japan).
  • Ulcerative colitis remains a key indication for potential partnership.

The big picture

OSE Immunotherapeutics is diversifying its pipeline by expanding lusvertikimab into high-need indications with strong biological rationale. The move aligns with broader trends in immuno-oncology and immuno-inflammation, where targeted therapies are gaining traction. The company’s strategy of balancing rare-disease opportunities with larger dermatology markets could enhance its long-term valuation, provided it secures necessary financing and demonstrates clinical success.

What we're watching

Financing Timelines
Whether OSE can secure funding to initiate Phase 2 trials by H2 2026.
Clinical Efficacy
How lusvertikimab’s performance in chronic pouchitis and hidradenitis suppurativa compares to its efficacy in ulcerative colitis.
Partnering Strategy
The pace at which OSE advances the subcutaneous ulcerative colitis program to attract potential partners.